Oncology
Beyond RECIST: How Digital Imaging Biomarkers Will Enhance Data in Oncology Trials
Oct 25, 2023VIDA
Description
In this conversation with Dr. Sheshadri, we'll explore advanced imaging biomarkers that offer additional depth and breadth of physiological information, not only for tumor response, but also for complications and side-effects of lung cancer therapies.
Highlights
Dr. Sheshadri explains what RECIST is and discusses its advantages and limitations.
Comparing the standardization of protocols in oncology trials to airway trials.
How imaging can help clinical trial inefficiencies.
" We're at a point where a lot of the technologies that we have might allow us to do this in a more sophisticated fashion "
"Some of the things that we measure in these airway trials, they don't change as much as a tumor changes.. ."
" One thing that is a problem in general is the standardization of imaging… "
Watch the Full Webinar
Access the full webinar for much more, including:
- Trends in oncology therapies
- Biomarkers in asthma
Speaker Bios
Ajay Sheshadri, MD, MSCI
Associate Professor, Department of Pulmonary Medicine, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX